Vumerity 231 mg gastro-resistant hard capsulesVumerity Placebo.
Le placebo utilisé aura les mêmes caractéristiques que le traitement à l'étude (Vumerity 231 mg) sur son aspect visuelson goût et sa formesans la molécule active. Il sera fourni par la société Synerlab Development.
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Absolute volume of PHO assessed at 8 ± 1 days with brain non-contrast CT (NCCT) scan.
Endpoint detail
Functional outcome: global disability assessed by overall distribution of mRS score at 6 months (end of follow-up) (shift analysis), Safety outcome: The rate of severe adverse events (see chapter 10 “Safety Assessment”) occurring between the date of randomization and the end of follow-up (six-month visit).
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.